A Long Term Open-Label Extension Study of Lersivirine For The Treatment Of HIV-1 Infection.

Trial Profile

A Long Term Open-Label Extension Study of Lersivirine For The Treatment Of HIV-1 Infection.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 18 Jul 2014

At a glance

  • Drugs Lersivirine (Primary) ; Darunavir; Efavirenz; Emtricitabine; Etravirine; Nucleoside reverse transcriptase inhibitors; Ritonavir; Tenofovir disoproxil fumarate
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 02 May 2013 Planned end date changed from 1 Aug 2017 to 1 May 2013 as reported by ClinicalTrials.gov.
    • 04 Apr 2013 Planned End Date changed from 1 Mar 2013 to 1 Aug 2017 as reported by ClinicalTrials.gov.
    • 01 Apr 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top